In addition to this, cyclin-dependent kinase-12 inhibitors have reversed de novo and developed PARP inhibitor resistance in breast cancer cells mutated due to the BRCA1 gene (Johnson et al., 2016). The gene discussed is BRCA1; the disease is breast carcinoma.